Vyne Therapeutics Inc (VYNE)

09:31 AM

Is VYNE Therapeutics Inc. a good long term investmentMassive profits - Autocar Professional

09:31 AM

07:37 AM

VYNE Therapeutics Inc. Stock Analysis and ForecastAccelerated financial growth - jammulinksnews.com

07:37 AM

Jul 22, 2025

What drives VYNE Therapeutics Inc. stock priceOutstanding capital returns - jammulinksnews.com

Jul 22, 2025

Jul 21, 2025

What analysts say about VYNE Therapeutics Inc. stockSuperior portfolio returns - Autocar Professional

Jul 21, 2025

Jul 18, 2025

Does VYNE Therapeutics Inc. stock pay reliable dividendsFree Capital Allocation Plans - Newser

Jul 18, 2025

Jul 16, 2025

How VYNE Therapeutics Inc. stock performs during market volatilityShort Term High Return Strategy - Newser

Jul 16, 2025

Jul 15, 2025

Why VYNE Therapeutics Inc. stock attracts strong analyst attentionAlpha Stock Ideas - Newser

Jul 15, 2025

Jul 15, 2025

What makes VYNE Therapeutics Inc. stock price move sharplyIntraday Trade Ideas - Newser

Jul 15, 2025

Jul 13, 2025

VYNE Therapeutics Inc. (VYNE) Gets Buy Reaffirmation on Pipeline Progress - MSN

Jul 13, 2025

Jul 11, 2025

VYNE Therapeutics: A High-Stakes Gamble on Vitiligo and Psoriasis - AInvest

Jul 11, 2025

Jul 08, 2025

Promising Potential of VYNE Therapeutics’ Repibresib Gel in Phase IIb Study - TipRanks

Jul 08, 2025

Jul 08, 2025

VYNE Therapeutics (NASDAQ:VYNE) Stock Price Down 9.5% – Should You Sell? - Defense World

Jul 08, 2025

Jul 07, 2025

VYNE Unblinds Early VYN202 Data After Safety Pause - Dermatology Times

Jul 07, 2025

Jul 03, 2025

BTIG reiterates Buy rating on VYNE Therapeutics stock ahead of vitiligo trial data - Investing.com Canada

Jul 03, 2025

Jul 03, 2025

H.C. Wainwright reiterates Buy rating on VYNE Therapeutics stock amid clinical hold update - Investing.com Canada

Jul 03, 2025

Jul 02, 2025

NOVT secures new $1B credit facility, extends maturity to 2030 | VYNE SEC FilingForm 4 - Stock Titan

Jul 02, 2025

Jul 02, 2025

VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202 - The Manila Times

Jul 02, 2025

Jul 02, 2025

VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202 | VYNE Stock News - GuruFocus

Jul 02, 2025

Jun 26, 2025

VOR Skyrockets On Ex-China Rights To Autoimmune Drug, ADIL To Face FDA On Jul.29, PSTV Jumps 14% - Nasdaq

Jun 26, 2025

Jun 25, 2025

Celebrating World Vitiligo Day 2025 with Dermatology Times - Dermatology Times

Jun 25, 2025

Jun 20, 2025

Vitiligo Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight - The Globe and Mail

Jun 20, 2025

Jun 18, 2025

Short Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Increases By 46.8% - Defense World

Jun 18, 2025

Jun 09, 2025

Jane Street Group LLC Invests $68,000 in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World

Jun 09, 2025

Jun 04, 2025

Northern Trust Corp Has $80,000 Stock Holdings in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World

Jun 04, 2025

May 30, 2025

VYNE Stock Touches 52-Week Low at $0.96 Amid Market Challenges By Investing.com - Investing.com South Africa

May 30, 2025

May 30, 2025

VYNE Therapeutics (NASDAQ:VYNE) Upgraded at Wall Street Zen - Defense World

May 30, 2025

May 29, 2025

VYNE Stock Touches 52-Week Low at $0.96 Amid Market Challenges - Investing.com India

May 29, 2025

May 25, 2025

VYNE Therapeutics (NASDAQ:VYNE) Cut to Sell at Wall Street Zen - Defense World

May 25, 2025

May 20, 2025

VYNE Stock Touches 52-Week Low at $1.17 Amid Market Challenges - Investing.com

May 20, 2025

May 11, 2025

VYNE Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

May 11, 2025

May 09, 2025

Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and CVRx (CVRX) - The Globe and Mail

May 09, 2025

May 09, 2025

VYNE Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 09, 2025

May 08, 2025

VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 08, 2025

May 08, 2025

VYNE Therapeutics: Strong Financial Position and Promising Drug Pipeline Justify Buy Rating - TipRanks

May 08, 2025

May 08, 2025

Vyne Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 08, 2025

May 08, 2025

VYNE Therapeutics Inc Q1 2025 Earnings: EPS of -$0.20 Beats Estimate, Revenue of $0.2 Million Exceeds Forecast - GuruFocus

May 08, 2025

May 08, 2025

VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update - The Manila Times

May 08, 2025